M. haemolytica outer membrane protein P1pE as a vaccine or vaccine component against shipping fever

Abstract

Vaccines and methods against M. haemolytica infections in cattle. The vaccine compositions include a recombinant outer membrane protein of M. haemolytica designated PlpE and/or subunits thereof, alone or in combination with other antigenic components, and a carrier or diluent. The methods involve administering an effective immunizing amount of the vaccines to susceptible bovine.

What is claimed is:  
     
         1 . A vaccine composition against infection of  M. haemolytica  in cattle comprising an effective immunizing amount of at least one immunogen selected from the group consisting of (i) recombinant PlpE outer membrane protein of  M. haemolytica,  (ii) an antigenic subunit of thereof, and (iii) recombinant PlpE outer membrane protein of  M. haemolytica  or antigenic subunits thereof in combination with at least one other antigen against  M. haemolytica , and further comprising a pharmaceutically acceptable carrier or diluent.  
     
     
         2 . The composition according to  claim 1 , wherein said carrier is an adjuvant.  
     
     
         3 . The composition according to  claim 1 , wherein said recombinant PlpE outer membrane protein of  M. haemolytica  comprises the polypeptide of SEQ ID NO: 2.  
     
     
         4 . The composition according to  claim 3 , wherein said subunits are selected from the group consisting of the polypeptides of SEQ ID NOS: 11-18.  
     
     
         5 . The composition of  claim 1 , wherein the subunit comprises the polypeptide of SEQ IDNO: 12.  
     
     
         6 . A method for inducing an immune response in cattle to provide immune protection against BRD and/or shipping fever, comprising administering to an at-risk bovine an effective amount of the vaccine composition of  claim 1 .  
     
     
         7 . The method according to  claim 6 , wherein the amount of vaccine composition includes between 10-100 μg of recombinant PlpE outer membrane protein of  M. haemolytica  or antigenic subunits of thereof.  
     
     
         8 . The method according to  claim 7 , wherein the amount of vaccine composition includes about 100 μg of recombinant PlpE outer membrane protein of  M. haemolytica  or antigenic subunits of thereof.